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 Several central nervous system related diseases involve various cellular 
inflammation related components.  Among others these components include increases in 
complement activation and synthesis of inflammatory signaling mediators.  Therefore, 
several strategies for creating therapeutic benefit in patients has centered on targeting 
these cellular inflammatory mechanisms.  One of these strategies has been to target the 
translocator protein (TSPO), which is an 18kDa outer mitochondrial membrane bound 
protein used in mediating transport of cholesterol into the inner mitochondrial membrane 
(Karlsetter, 2014).  Recent studies have shown that activation of TSPO can induce a 
cellular anti-inflammatory response.  The immunomodulation of the anti-inflammatory 
process is generally controlled by cytokines such as interleukin-10.  So far, several 
protein, small molecule and peptide agonists, which stimulate the production of IL-10, 
have been elucidated.   Recently Karlsetter et al displayed a cellular model where the 
potent inflammatory effects of lipopolysaccharide (LPS) were reduced with an increasing 
concentration of TSPO.  This data and other evidence hint at a mechanism where TSPO 
induces an anti-inflammatory response by upregulating IL-10.  Therefore I propose that 
IL-10 mRNA and IL-10 protein levels are elevated within immune cells when TSPO 
levels have been overexpressed.  To test this, TSPO was stimulated with Etifoxine, a 
known TSPO ligand, and evaluated for increases in IL-10 mRNA and protein.  Gene 
expression and protein production data showed that no concentration or incubation of 
Etifoxine was able to upregulate IL-10 mRNA or protein.  Furthermore, stable 
 overexpression of TSPO in a macrophage cell line was unable to induce any increase in 
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Chapter I  
Introduction 
 
Inflammation is a normal and regulated defense system the body employs in 
response to harmful stimuli such as infectious agents and cellular and tissue injury.  
Generally, cellular inflammation can be defined as the process of recruiting and directing 
leukocytes to the damaged tissue through processes called margination and extravasation 
(Krishnamoorthy, 2006, Medzhitov, 2008).  
 
Margination and Extravasation  
The process of margination begins when the damaged cell releases a variety of 
inflammatory chemical mediators such as the inflammatory cytokine families interleukin 
and TNF0""Vjgug"ejgokecn"ogfkcvqtu"yknn"ÐcevkxcvgÑ"vjg"gpfqvjgnkcn"egnnu"uwttqwpfkpi"vjg"
capillary wall and will initiate the transfer of the cell adhesion molecule P-selectin, 
normally sequestered within granule bodies, to the cell surface.  The appearance of P-
selectin on the cell surface will prompt the recruitment of leukocytes by attracting them 
to the capillary wall where adhesion molecules found on both the activated endothelial 
cells and the attracted leukocytes will bind, form a complex, and halt the migration of the 
leukocytes.  This recruitment of leukocytes to the vascular endothelium is a featured 
characteristic of the inflammatory process (Hunt, 1998, Szmitko, 2003). 
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Extravasation is the process in which the bound leukocytes migrate from the 
capillary wall to the site of inflammation via chemical stimuli.  Initiation of this process 
occurs when mast cells de-granulate and release the vasodilators histamine and 
prostaglandin.  An increase in the basal level of these vasodilators induces the arrested 
leukocytes to rearrange their cytoskeleton and pass through the gaps in the vascular 
endothelium (Krishnamoorthy, 2006, Medzhitov, 2008).  This complicated yet elegant 
process of detecting and destroying foreign antigens begins moments after pathogen 
kphgevkqp0""C"rtkoct{"tgcuqp"hqt"vjg"dqf{Óu"swkem"tgurqpug"ku"fwg"vq"vjg"egnn"v{rgu"hqwpf"
in the immune system.    
 
Innate Immune System Phagocytes 
Although the main cell type in the innate immune system is the white blood cell, 
several other leukocytic cell types and subclasses are involved in the identification and 
eventual clearance of the infecting pathogen.  One specific type of sub-class is a 
rjciqe{vg."yjkej"eqpukuvu"qh"vjg"egnn"v{rgÓu"oqpqe{vg."ocuv."fgpftkvke."pgwvtqrjkn"cpf"
macrophage (Flannagan, 2012).  Phagocytic cells are the main cell type responsible for 
engaging the immunogenic foreign substance found in the body, isolating it, and then 
eliminating it.  Elimination occurs through receptor-mediated binding of the phagocyte 
and the host pathogen.  Once a complex is formed, the phagocyte engulfs the pathogen 
and stores it in a phagosome.  The phagosome then combines with a lysosome to form a 
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phagolysosome where the pathogen is eventually destroyed by pH dependent enzymes 
(Flannagan, 2012).   
Mast cells and neutrophils can also be categorized as granulocytes due to the large 
presence of protein rich granules in their cytoplasm.  Although mast cells play a role in 
the innate immune system they are also well known for their role in allergic response due 
to the rapid release of histamine when bound to immunoglobulin E (Thompson-Snipes, 
1991, Hunter, 2005, Rocha, 2014).  Neutrophils are the most abundant type of leukocytes 
found in the body and therefore are the cells primarily responsible for the phagocytosis of 
foreign particles (Amulic, 2012, Flannagan, 2012).  Along with their ability to 
phagocytose pathogens, dendritic cells can also migrate to the lymphoid, bind with T and 
B cells and initiate the adaptive immune system (Ganguly, 2013, Flannagan, 2012).     
Monocytes are unique in that they have the ability to differentiate into both 
macrophage and dendritic cells.  This differentiation ability allows them to continually 
replenish the body with macrophage and dendritic cells, giving the body an ample storage 
of phagocytic cells.  Other hallmark features of the monocyte is its ability to produce pro 
and anti-inflammatory cell signaling molecules such as IL-1 and IL-10, as well as its 
ability to present antigen to T-cells for the adaptive immune system (Auffray, 2009, 
Flannagan, 2012). 
For the purposes of an anti-inflammatory therapeutic target, macrophage cells 
may be the most appealing.  Macrophage cells can be classified into two subsets, class 
M1 and class M2.  Primarily this classification dictates how the macrophage will respond 
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to the pathogen.  Activated M1 macrophages function primarily as a first line of defense, 
since they tend to be highly aggressive and will produce large amounts of pro-
inflammatory cytokines such as IL-6 and IFN-Ȗ"*Oknnu."4234."Owttc{."4233."Owttc{."
2011).  Alternatively, activated M2 macrophages perform various anti-inflammatory 
functions such as suppressing antitumor immunity, upregulating the secretion of the anti-
inflammatory cytokines such as IL-10 and initiating the wound healing process.  
Subsequently, activated M2 macrophages can also induce the differentiation of precursor 
monocytes into a M2 macrophage phenotype, thereby increasing the M2 colony size and 
aggregating their anti-inflammatory effect (Murray, 2011).  Additionally, both classes of 
macrophages can be found throughout the body, which makes the production of anti-
inflammatory cytokines such as IL-10 through a M2 phenotype more appealing as a 
therapeutic target.  For the context of neurodegeneration and inflammation the brain 
induces its own anti-inflammatory response through a subclass of the macrophage cell 
type known as the microglia cell (as discussed below).   
 
The role of Interleukins in Inflammation 
Phagocyte recruitment, proliferation and their functions are very much governed 
by the actions of the chemical signaling group known as Interleukins (IL) (Asadullah, 
2003).  Interleukins, along with chemokines, interferons and colony stimulating factors 
are grouped into a larger collection of cell signalling proteins called cytokines.  Upon the 
onset of inflammation several pro-inflammatory cytokine family members, such as IL-1 
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and TNF-g become upregulated and their protein concentrations increase (Khadka, 
2014).  For example during the onset of an allergic reaction, T-helper cells will produce 
IL-4, IL-5, IL-9, and IL-32, which then begins the production of allergen specific IgE 
(Khadka, 2014).  This and other action in response to disease allows the body to 
continuously counteract any pathogenic threat.   
One of the more promising biological therapeutic targets in inflammation is 
considered to be IL-10.  A primary reason for the interest in IL-10 lies in its production 
by a large variety of cell types, including monocytes, macrophages, mast, dendritic, 
neutrophil and B and T lymphocytes (Ocuin, 2011, Lies, 2001, Chaco, 2011, Rong-Jiang, 
2002).  As a noncovalently linked homodimeric cytokine, IL-10 has many proven anti-
inflammatory and immunosuppressive activities (Gerard, 1993, Wiendl 1999, Lauw, 
2002).  In vitro studies have found that IL-10 can up-regulate many of the inflammation 
suppressing activities in monocytes and macrophages by modulating their cell 
proliferation and reducing the production of TNF, IL-3ȕ."KN-6, IL-8, and IL-12 cytokines 
(De Waal, 1991).  IL-10 has also been shown to inhibit similar characteristics in T and B 
cells (De Waal, 1993).  In vivo studies where recombinant IL-10 was administered, prior 
to lethal administration of LPS and staphylococcal enterotoxin B, demonstrated increased 
protection and decrease in pathogen (Gerard, 1993, Bean, 1993). 
Mechanistically, the anti-inflammatory pathway for IL-10 is receptor-mediated 
and begins when the cytokine binds to the extracellular domains of the IL-10 receptors 1 
and 2 forming a multi protein complex.  This binding facilitates phosphorylation of the 
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cell signaling kinases JAK1, TYK-2, while also phosphorylating ERK1/2 of the MAP 
family of kinases.  These phosphorylation events lead to the docking of the transcription 
factor STAT3.  After binding, STAT3 will become phosphorylated translocate to the 
nucleus and bind to STAT-binding elements in the promoters of various response genes 
such as Cyclin-D1, c-Myc and p19. (Table 1) (Donnelly, 1999).  
 
Neuronal Inflammation 
Initiation of inflammatory processes in the central nervous system (CNS) displays 
a similar pattern of cytokine synthesis, endothelial vasodilatation and immune cell 
migration consistent with the rest of the body.  Generally, neuronal inflammation has a 
beneficial effect in any particular disease and in any particular phase of a disease.  
However, loss of control in any one of several mechanisms previously mentioned can 
lead to sustained neuronal inflammation, a common characteristic found in several 
pgwtqfgigpgtcvkxg"fkugcugu"uwej"cu"Cn|jgkogtÓu."RctmkpuqpÓu."cpf"ownvkrng"uengtquku"
(Aktas, 2007, Brown, 2010).   
Although several aspects of the innate and adaptive immune system are preserved 
in the CNS, the presence of the blood brain barrier (BBB) distinguishes the CNS from the 
periphery.  The BBB, a selectively permeable barrier consisting of a vast bed of tightly 
packed capillary endothelial cells, ensures that peripheral cells such as leukocytes are 
inhibited from entering the CNS (Brown, 2010).  This exclusion results in glial cells, a 
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neuron supporting cell, functioning as the predominant immune cells found in the brain 
(Gyoneva, 2014).   
A subclass of glial cells called microglia is considered to be the resident 
macrophage in the brain.  Like many other macrophages, microglia can exist in a resting 
state associated with normal cell function and tissue surveillance or they can become 
activated and adopt either an M1 or an M2 phenotype (Crain, 2013).     
Historically, microglia cells were overlooked in the CNS due to their assumed 
role as a phagocyte and the relative difficulty of obtaining non-activated sub cultures 
(Brown, 2010).  However, recent experimental advances in two-photon laser microscopy 
and tissue culture methods have elucidated current understandings that microglia cells 
can actively support neurogenesis and aid in the structure and maintenance of neuronal 
networks (Sierra, 2010, Tremblay, 2011, Stansley, 2012).  They have also demonstrated 
the capacity to secrete and upregulate several protective and growth-promoting 
neurotrophic factors including nerve growth factor (NGF), neurotrophin-3 (NT-3), brain-
derived neurotrophic factor (BDNF) and insulin-like growth factor (IGF-1) (Elkabes, 
1996; Nakajima, 2001, Mizuno, 2000, Hsieh, 2004).  
Studies investigating the targeting of microglia M1 activation have shown 
reductions in amyloid beta production and tau protein accumulation in mouse models for 
Cn|jgkogtÓu"cpf"RctmkpuqpÓu"fkugcug"tgurgevkxgn{"*Etchv."4226."Ejw"Yw."4224."
Anichtchik, 2000).  It has also been reported that stimulation with the anti-inflammatory 
cytokine interleukin 10 (IL-10) is able to inhibit M1 microglial activation and increase 
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M2 microglia cells (London, 2013, Chabot, 1999, Heyen, 2004).  Taken together, 
therapeutic intervention by IL-10 stimulation for the deactivation of M1 microglia and 
upregulation of M2 microglia may be an effective strategy for neurodegenerative 
diseases.  This emphasizes the concept that modulating immune system pathway 
members, such as IL-10, may be an effective regulator of neuronal inflammation.      
 
Current Neuronal Immune Modulating Therapeutic Strategies 
It has been established that delivery of therapeutic molecules to the CNS using 
conventional methods, such as oral and intravenous administration, has been limited by 
diffusion across the BBB (Kastin, 2003).  However, advancements with viral vectors, 
transcranial surgery techniques, focused ultrasound, intranasal administration, absorptive 
endocytosis and receptor mediated endocytosis have demonstrated increased BBB protein 
delivery (Gabathuler, 2010).  Apart from these improvements, industry and academic 
institutions alike have studied neuronal immune system modulators for therapeutic 
benefit.     
Recent work has shown that pharmacological inhibition of monocyte 
chemoattractant protein 1 (MCP-1), which is a known monocyte recruiter and 
inflammation proliferator, reduced neuronal inflammation in-vivo (Sawyer, 2014).  
Another study demonstrated both in-vivo and in-vitro how blockage of the plexin C1 
receptor (PLXNC1), a recently discovered receptor for neuronal guidance proteins and 
known mediator of monocyte activation, was associated with reduction in rolling, 
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adhesion and chemotactic transendothelial migration of leukocytes during onset of 
inflammation (Konig, 2014).      
Progranulin (PGRN), a highly conserved and widely distributed CNS protein has 
been implicated in assisting cell growth, wound healing and inflammation (Baker, 2006).  
By overexpressing PGRN through viral gene delivery in-vivo, nigrostriatal neurons were 
protected and preserved from inflammation induced by chemical induced toxicity (Van 
Kampen, 2014).  Taken together, these approaches prove that neuronal inflammation can 
be regulated effectively by altering proteins associated with immune system members.  
However, a more efficient, effective and specific immune system modulation may be 
achieved by utilizing the well-researched and highly potent cell-signaling group 
interleukins.   
 
Current Therapeutic Strategies Targeting IL-10 
Due to the potent and effective anti-inflammatory properties of IL-10, it has 
become an ideal candidate for the therapy of several immune diseases (Kaminska, 2009).  
As a stand-alone protein injected intravenously, IL-10 can inhibit brain TNF-g"
production induced by a direct brain injection of the endotoxin LPS (Di Santo, 1997).  
Other groups have administered recombinant IL-10 prior to and after inducing traumatic 
brain injury and have found improved neurological recovery and significantly reduced 
TNF-g"cpf"KN-1 expression in the hippocampus and cortex (Knoblach, 1998, Spera, 
1998).       
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Unfortunately, these in-vitro and in-vivo therapeutic effects do not appear as of 
yet to correlate to efficacious clinical findings (Asadullah, 1999, 2002, Colombel, 2001, 
Lauw, 2000, Tilg, 2002, Schwager, 2009).  Although a recombinant version of IL-10 may 
be unable to elicit a clinical benefit, there still may be an advantage to stimulating IL-10 
by modulating known inducers.  For example, a recent group created a modified peptide 
of granulocyte-macrophage colony-stimulating factor and the chemokine CCL7.  
Together these proteins exert increased inhibition of antigen presentation and a marked 
reduction of TGF-ȕ"cpf"KN-6.  This led to production of differentiated Th17 cells by 
inducing the production of IL-10 producing B-cells (Hsieh, 2012).   
Another recent approach involved using lentivirus to genetically modify the 
mouse genome in order to increase endogenous levels of IL-10.  This modification 
significantly reduced gene expression of pro-inflammatory cytokines IL-17 and IL-23 
(Hiryama, 2013).   
It has also been reported that levels of IL-10 can be upregulated in activated M1 
microglia while simultaneously suppressing levels of pro-inflammatory cytokines when 
stimulated with the purine nucleotide adenosine a ligand known to suppress TNF-g"
production (Koscso, 2012).  Inhibition of activated M1 microglia through a vanilloid 
receptor (VR) agonist has also been reported (Lin, 2007).  These and other findings 
demonstrate that inducing IL-10 through protein, small molecule antagonists and 




The translocator protein (TSPO) is an 18kDa outer mitochondrial membrane 
bound protein used in mediating transport of cholesterol into the inner mitochondrial 
membrane (Veenman, 2007).  Originally, research elucidating the structure and function 
of TSPO were done using ligands for the neurotransmitter gamma-aminobutyric acid 
receptors (GABA).   Consequently, the initial name given to the protein was peripheral 
benzodiazepine receptor (PBR).   Further research of this protein has determined that it is 
constitutively expressed throughout the body and considered to have numerous functions 
in various host defense systems, cell proliferation and differentiation, apoptotic processes 
and mitochondrial membrane functions (Veenman, 2012).  Due to these compounding 
processes groups have found that TSPO is upregulated in several CNS related diseases 
uwej"cu"Cn|jgkogtÓu."JwpvkpivqpÓu."co{qvtqrjke"ncvgtcn"uengtquku."RctmkpuqpÓu"cpf"
multiple sclerosis (Karlstetter, 2014, Wei, 2013, Sook, 2014).  More importantly, recent 
studies have shown that upregulation and agonism of TSPO by several different 
benzodiazepine drugs can induce a cellular anti-inflammatory response (Choi, 2011, 
Kugler, 2008, Barron, 2013, Girard, 2008). 
Specifically, TSPO ligands can reduce neuronal death by decreasing the number 
of proliferating microglia and antigen-presenting MHC-II cells in the hippocampus of 
male rats after intracerebroventricular infusion of LPS (Veiga, 2007).  Additionally, 
VURQ"nkicpfu"jcxg"cnuq"ujqyp"vjg"cdknkv{"vq"tgfweg"Cn|jgkogtÓu"fkugcug"rcvjqnqi{"d{"
tgfwekpi"ȕ-amyloid accumulation, reducing microglia proliferation ip"Cn|jgkogtÓu"oqwug"
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model (Barron, 2013).  Furthermore, data obtained using TSPO ligands on human 
glioblastoma cells found that voltage gate dependent mitochondrial membrane potential 
was preserved while several apoptotic factors including cytochrome c, caspase-9 and 
caspase-3 were reduced (Kugler, 2008). 
Interestingly, a study conducted by Choi, et al., found that the TSPO agonist Ro5-
4864 reduced the expression of the pro-inflammatory cytokine TNF-g (Choi, 2002).  A 
follow up study conducted by the same group showed that administration of the TSPO 
antagonist PK-11195 could decrease the proliferation of active microglia and the levels of 
reactive oxygen species (Choi, 2011).  These data indicate that altering levels of TSPO, 
through either agonist or antagonist action, can result in the activation of alternate 
immune modulating pathways which can result in various beneficial effects. 
 
Etifoxine 
Etifoxine, a clinically approved anti-anxiety and anticonvulsant agent, is a potent 
TSPO ligand in part because of its ability to bind to both sub classes of GABA receptors 
(Schlichter, 2000).  Due to this high affinity, several groups have conducted experiments 
determining the effect of this ligand in the CNS and have demonstrated a down-
regulation of microglia activation and a promotion of neuronal cell survival and repair 
(Girard, 2008, Ugale, 2007).   
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In a separate study Girard, et al., also found that stimulated PC12 cells, increased 
neurite outgrowth which is an indication of neuronal proliferation.  Behavioral in-vivo 
experiments performed by the same group revealed that increasing concentrations of 
etifoxine improved recovery of locomotion, motor coordination, and sensory functions 
(Girard, 2008).  Additionally Daugherty, et al., demonstrated that etifoxine administration 
led to a decrease in immune cell infiltration across the BBB and a reduction in 
inflammatory demyelination.  These changes directly lead to etifoxine administration 
attenuating the progression of inflammatory pathology in a mouse model of multiple 
sclerosis (Daugherty, 2013).  Although several experiments have shown that TSPO and 
its ligands are able to inhibit and reverse the inflammatory response, no mechanistic 
relationship has yet to be established that shows this effect is controlled by upregulation 
of the anti-inflammatory cytokine IL-10. 
 
Summary Proposal of Present Investigation 
Therefore, I proposed a comprehensive strategy to directly observe the regulation 
of IL-10 genetic expression and protein production when stimulated by TSPO.  The 
experiments were conducted in-vitro using the mouse macrophage cell line RAW264.7 
and the mouse microglia cell line C8-B4.  In order to assess gene regulation changes, 
qualitative polymerase chain (qPCR) reaction assays were employed.  Following those, 
mouse specific IL-10 enzyme linked immunosorbent assays (ELISA) were completed to 
determine the amount of protein being produced from TSPO stimulation.  Controls for 
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each endpoint assay included an untreated negative control and the highly potent 
endotoxin Lipopolysaccharide (LPS).  Increases in IL-10 mRNA and protein, comparable 
to the LPS positive control, following TSPO stimulation will indicate a positive TSPO 
effect.   
The innate and adaptive immune systems are both exceptionally complex and 
highly conserved throughout the body.  Identifying key regulators is essential to 
increasing our understanding and discovering novel therapies.  Knowledge from these 
experiments may enhance our current understanding of how TSPO ligands induce an 











Chapter II  
Materials and Methods 
 
Several techniques and experiments were employed in this study in order to verify 
whether modulation of TSPO is able to induce an up-regulation of IL-10.  These included 
cell culture, vector construction and lentivirus production, viral infection, RNA 
manipulation, real time polymerase chain reaction (RT-PCR), western blot and enzyme 
linked immunosorbent assay (ELISA).  Please find below reagents used and the specific 
steps and details associated with each technique. 
 
Reagents 
All reagents were used in agreement with the manufactures explicit instructions.  
The cell lines RAW264.7, C8-B4 and HEK-293T were acquired from ATCC.  Lentiviral 
vectors and virus packaging were from Origene Technologies.  RNA extraction and 
purification products were obtained from Qiagen.  RT-PCR reaction kits and associated 
products and machines were from Applied Biosystems.  Mouse IL-10 ELISA kits were 
from R&D Systems.  TSPO primary and Donkey anti-Goat secondary antibody were 
from Thermo-Fisher.   
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Cell Culture and Media Prep 
The cells used in this study included mouse macrophage cells RAW264.7 
(ATCC), the mouse macrophage microglia cell line C8-B4 (ATCC) and the human 
embryonic kidney cell line HEK-293T (ATCC).  Each cell line was grown kp"FwndgeeqÓu"
Oqfkhkgf"GcingÓu"Ogfkwo"*Ikdeq1Invitrogen) completed with 10% fetal bovine serum 
(Gibco/Invitrogen).  Cryopreserved cells were thawed and placed into 75 cm2 culture 
flasks with fresh medium.  Cultures were then allowed to incubate at 370C with 5% CO2 
in air atmosphere until a viability of over 95% was achieved.  Viability was determined 
using a Cedex cell counter and analyzer (Roche Biotech).  Subculturing for maintenance 
and experimentation included removing of media from healthy cells and washing with 
Hanks Balanced Salt Solution (HBSS, Gibco/Invitrogen) followed by addition of 0.25% 
Trypsin (Gibco/Invitrogen) for 5 minutes.  Detached cells were removed, placed into the 
appropriate tube size and spun at 125g for 5 minutes.  After which the cell pellet was 
resuspended in fresh culture media and counted on the Cedex to determine total number 
of cells needed for specific task. 
 
Vector Construction 
The TPSO gene portion of the vector used (Origene, RC220107) was cut out 
using the restriction digest enzymes SgfI and MluI by polymerase chain reaction (PCR), 
amplified and cloned into the following lentiviral vectors: 
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‚ pLenti-C-mGFP (Origene PS100071) 
‚ pLenti-C-myc-DDK (Origene PS100064) 
‚ pLenti-C-IRES-Puro vector  
The pLenti-C-IRES-Puro vector was created by replacing the mGFP portion of 
the pLenti-C-mGFP vector with the IRES-Puro fragment portion from the pTripZ vector 
(GE healthcare RHS4696).  Vector maps can be found on Table 2 in the appendix. 
 
Lentivirus Production and Viral Infection 
For production of second-generation lentivirus, 293T/17 cells (ATCC) were co-
transfected with three plasmids using the manufacturers protocol for Lipofectamine 2000.  
Briefly, the cloned lentiviral plasmids (5ug) described above were mixed with lentiviral 
packaging plasmids psPAX2 and VSV-G envelope encoding pMD2.G (5ug) in 250uL of 
Opti-MEM.  Simultaneously, 20ul of Lipofectamine was added to 250ul of Opti-MEM 
and incubated for 5 min at room temperature (RT).  The two fractions were then gently 
mixed and allowed to rest for 15 min at RT.  This plasmid mixture was then added to 
293T cells that had reached 80-90% confluence in T-25 flasks.  After 20 hours of 
transfection, the medium was replaced with fresh medium and viral supernatant was 
harvested 24 hours later.  Virus supernatant was filtered using a 0.45 µm filter (Millipore, 
Bedford, MA) to remove cells debris before use for transducing target RAW cells.  Raw 
cells were incubated with virus for at least 24 hours and no more than 72 hours prior to 
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virus removal.  GFP levels were estimated through fluorescent microscopy to determine 
percentage of virus infection. 
 
RNA Manipulation 
RNA was isolated from the specific cell type utilizing the RNeasy Mini Kit 
(Qiagen).  Cultured cells were washed with HBSS and immediately lysed with kit 
provided RLT lysis buffer with kit provided RNAse inhibitor for 5 minutes at room 
temperature.  Lysed cells were then centrifuged for 3 min at maximum speed.  The 
supernatant was separated and was mixed with 1 part 70% ethanol and then transferred to 
a kit provided RNeasy spin column and collection tube.  Column was then spun and 
washed with supplied wash buffer several times prior to elution with DNAse/RNAse free 
water.  Determination of sample RNA purity and quantity was based on the values 
obtained by A260/A280 measurement (Nano Drop, Thermo Fisher).  
 
Western Blot 
 Prior to loading the western blot protein lysates were prepared from cultured cells.  
A 1:1000 part of protease/phosphatase inhibitor cocktail was added to the cell lysis 
reagent Celllytic (Sigma).  After washing, cells were lysed and placed into individual 
tubes and subjected to 4 separate 15 minute incubations on ice followed by vigorous 
vortexing.   Following the final incubation lysates were centrifuged at maximum speed 
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for 15 minutes.  Total protein concentration of lysates was determined via addition of 
bicinchoninic acid assay (BCA) solution to the supernatant of the spun down lysate, 
followed by a 30-minute incubation at 370C.  Absorbance increases from the chemical 
reaction were read on a spectrophotometer and back calculated to a known concentration 
of bovine serum albumin.   
 1ug of total protein lysates were reduced with SDS buffer in 950C for 5 minutes 
prior to being loaded onto a precast 14% SDS-PAGE gel (Invitrogen).  Gels were run 
under normal reducing conditions.  Membranes were blocked with PBS-T with 5% milk 
overnight prior to the addition of a TSPO primary antibody (PA5-18565) for 1 hour and 
addition of an HRP conjugated Donkey anti-Goat secondary antibody (PA1-28664) for 1 
hour.  Film exposure using a CCD camera after incubation of a membrane with TMB 
substrate allowed for determination of protein size compared to a known protein control. 
 
Statistical Analysis 
Quantitative values obtained in a given experiment are expressed as the average 
of all replicates in that particular experiment.  Standard deviation was performed on all 
sample groups and was used to determine deviation from the mean (means + SD).  All 
experiments were evaluated, graphed and analyzed evaluated by using Prism software 
(GraphPad).  Student t-tests (two-tailed) were performed to compare differences between 
untreated and treated samples.  P values were considered significant if p <0.05.  In-Vitro 
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experimental treatment groups were done in triplicate unless otherwise stated and 
experiments were repeated at least twice. 
 
Gene Expression and Protein Production Experiments 
In order to determine the gene expression of IL-10 quantitative polymerase chain 
reactions (qPCR) were used as an endpoint.  Following normal culture methods 
RAW264.7 cells were plated onto a 12 well tissue culture plate at 3x10^5 cells per well.  
After an overnight incubation the cells were either left untreated (- Ctrl), treated with the 
1ug/mL LPS (+ Ctrl) or with the TSPO ligand Etifoxine.  Various concentrations and 
incubation times were used for stimulation in order to determine an optimal condition and 
to observe any possible dose response (Table 5, 6 and 7).  After the cells have been 
stimulated the RNA was extracted using the RNeasy kit manufactured by Qiagen.  The 
resulting RNA samples were then measured by spectrophotometer at 260 and 280nM 
respectively, concentration was calculated and RNA quality was noted.  50ng of extracted 
RNA along with reaction buffer and either IL-10 or ribosome subunit 18 (18s) assay 
probes were loaded onto a qPCR specific reaction plate and run using manufactures 
recommended settings (Table 3 and 4).  Resulting gene expression data from IL-10 
samples were normalized by endogenous levels of 18s and compared to an untreated 
assay reference sample.  This method, known as the ǻǻEV comparative, has allowed for 
an analysis of the changes in gene expression levels between ligand treated samples and 
untreated controls. 
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The endpoint for determining IL-10 protein production is a commercially 
available ELISA kit from R&D systems.  Culture method, plate selection, cell 
concentration and IL-10 stimulation concentrations is exact to conditions established for 
the gene expression experiment.  Since IL-10 is a secreted protein, extraction of IL-10 
included removal of the cultured media after the given incubation time.  The samples 
were then analyzed in triplicate using the R&D systems IL-10 ELISA protocol.  Protein 
production levels were based on absorbance of a substrate bound to an IL-10 antibody.  
Increasing amounts of absorbance indicate a larger production of protein.  Samples were 
compared to each other and significance was determined via student t-test.  Experimental 
approaches and a typical plate layout have been summarized in the appendix (Table 5 and 
7).   
If IL-10 is modulated by TSPO overexpression then similar results could be 
expected but not assumed throughout other cell types and tissue.  To test this I utilized 
the assays and conditions established above and test the hypothesis on the C8-B4 cell 
line.  C8-B4 cells are macrophage/microglia cells derived from the brain tissue of an 8-
day-old male mouse.  The cells were cultured in media consisting of ATCC-formulated 
Dulbecco's Modified Eagle's Medium combined with 10% FBS.  Microglia cells are good 
candidates for this experiment due to their macrophage like properties and their ability to 








Several experiments were performed in order to determine whether or not the up-
regulation of IL-10 is directly responsible for the observed anti-inflammatory effects of 
TSPO.  These experiments included gene expression and protein production of IL-10.   
 
Gene Expression 
To induce a strong initial expression of IL-10 mRNA the first dose response 
experiment performed used a limited dilution of Etifoxine starting at a total concentration 
of 1mg/mL and ending at 10ng/mL (Figure 1).  RAW cells were first plated into a 12-
well tissue culture plate at a density of 3x105 per well and allowed to adhere overnight.  
The cells were then either left untreated or were treated with the various concentrations of 
Etifoxine or the positive control LPS (1ug/mL) for a total of 4 hours at 370C.  Based on a 
normal visual evaluation of cellular structure via microscopy, cells treated with Etifoxine 
at 100ug/mL and over were deemed to be undergoing unusual cellular morphologic 
changes.  These changes included loss of membrane permeability, reduction in cellular 
attachment and an overall increase in cell lysis that can be attributed to apoptosis.  
Therefore concentrations over 10ug/mL can be considered toxic and any gene regulation 
that may be occurring could be caused by the cellular stress associated with the toxicity.  
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Taking the visual toxicity into consideration, only cells treated with concentrations lower 
than 10ug/mL were analyzed for IL-10 mRNA upregulation.  Unfortunately, compared to 
the LPS positive control no concentration of Etifoxine deemed non-toxic stimulated the 
production of IL-10 mRNA within the RAW cells.  
Following the first dose response experiment, a second dose response experiment 
was performed with a few modifications in order to reduce any toxicity observed from 
the higher concentrations of Etifoxine.  The incubation time was also increased to 16 
hours in order to determine if IL-10 gene expression modulation through TSPO ligand 
binding occurs after the original 4-hour incubation (Figure. 2).  Similar plating and 
culture conditions to the first dose response experiment were utilized.  Concentrations of 
Etifoxine were changed to a dilution of 20ug/mL maximum dose to 1ng/mL minimum 
dose.  Normal visual evidence determined that no cells treated with the concentrations of 
Etifoxine mentioned were undergoing cellular stress due to toxicity and the 
concentrations were deemed to be tolerable.  Similar results were seen as compared to the 
first experiment with only the LPS positive control obtaining statistical significance 
compared to the untreated negative control.  
Although different doses of Etifoxine were unable to stimulate IL-10 gene 
expression one possible reason could be due to the rapid transcription of the genetic code 
within the cell.  If the IL-10 genetic message is being created quickly then perhaps the 
incubation times I examined in the first two dose response experiments were too long to 
detect significant levels of mRNA.  Another reason may be that the incubation times 
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utilized were too short in order to detect small amounts of message, thus a longer time 
point may be necessary in order for the cell to produce the concentration needed for the 
RT-PCR to observe it.  In order to identify this kinetic response of IL-10 mRNA 
expression by TSPO stimulation a time course experiment was completed.  Following the 
similar methods to the previous dose response experiments, RAW cells were plated in a 
12-well tissue culture plate and were either left untreated or were treated with a fixed 
concentration of 1ug/mL of Etifoxine or 1ug/mL of LPS for the given times stated 
(Figure 3).  After incubation RNA was obtained as previously described and each time 
point was analyzed for IL-10 mRNA levels.  The LPS treated and untreated wells were 
collected at the 24-hour time point.  Results indicate that no time period was able to 
induce the expression of IL-10.  
Since Etifoxine treatment was unable to produce any significant reaction with 
various doses and with various incubation times, other well-known TSPO ligands were 
obtained in order to determine if the current Etifoxine molecule obtained was inactive or 
ineffective.  The other small molecules conskuv"qh"6ƍ-Chlorodiazepam (Ro5-4864), 
PK11195 and N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide.  Each molecule is 
classified as potent selective ligand of TSPO and has shown to be neuroprotective in 
several studies (Choi, 2011).  While using the newly obtained ligands of TSPO, a final 
RAW cell gene expression experiment was completed (Figure 4).  Each ligand was used 
at concentrations of 1ug/mL and 10ug/mL and were compared directly to Etifoxine and 
the positive control LPS.  The doses were placed onto the cells for a total of 4 hours.  
Minimal cell loss was observed from any treatment therefore the concentrations used 
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were deemed to be tolerable.  Unfortunately, no significant upregulation of IL-10 mRNA 
was seen between any of the treated groups at any concentration.  The positive control 
LPS proved to be statistically significant. 
Although RAW cells are a purified macrophage cell line and should be able to 
produce significant amounts of IL-10 with the correct stimuli, the tissue of origin is non 
neuronal.  Since many of the studies have provided evidence that TSPO induces its 
effects in the CNS then perhaps non-neuronal tissue types do not have the proper cellular 
machinery for TSPO interaction.  Therefore, mouse microglia cell line C8-B4 was 
cultured and used in further IL-10 gene expression assays.  Although these cells are also 
non-neuronal they do provide context into the neuronal environment.  Mimicking the first 
IL-10 gene expression experiment method, C8-B4 cells were plated and allowed to 
adhere to a 12-well plate overnight.  The following day Etifoxine was administered at 
.001, .1, 1 or 10ug/mL for a total of 4 hours (Figure 5).  The positive control LPS was 
also administered at a concentration of 1ug/mL.  Results indicate that only the positive 
control was able to produce any relevant amount of IL-10 mRNA. 
In order to verify whether a longer or shorter incubation time is needed in order to 
observe any IL-10 upregulation a time course experiment was performed on the C8-B4 
cells.  After Etifoxine administration cells were incubated for 2, 4, 8 and 24-hour time 
points (Figure 6).  Comparing each treatment group to the untreated control there was not 




Low levels of gene expression usually result in low levels of protein production.  
Normally if vjgtg"ctgpÓv"nctig"coqwpvu"qh"vtcpuetkdgf"oTPC"vjgp"uocnngt"coqwpvu"qh"
ribosomal proteins will be needed in order to translate the message into protein.  
However, it is possible that the lower limit of detection for the RT-PCR method is unable 
to detect extremely small quantities of IL-10 mRNA expression and these low levels 
could still be able to created significant amounts of IL-10 protein.  In order to determine 
IL-10 protein production, RAW cells were plated and either left untreated or 
administered Etifoxine or LPS.  Since IL-10 is secreted, significant amounts of the 
protein can be evaluated through obtaining the cultured media of treated cells and 
assaying for total IL-10 through the ELISA method.  Subsequently, cell culture media 
from all the gene expression experiments were saved until such time that the IL-10 
protein production could be assayed.  As was seen with the gene expression of IL-10, no 
subsequent levels of protein were obtained from the various dose response experiments in 
either the RAW or C8-B4 cell treated experiments (Figure 7, 8 and 11). 
We next evaluated whether RAW or C8-B4 cells are able to produce IL-10 
protein following a series of incubations (Figure 9 and 12).  For both experiments a fixed 
1ug per well concentration of Etifoxine was used to stimulate the production of IL-10 
protein.  The untreated and LPS treated control samples were removed at 24 hours post 
administration.  Remarkably, an increase in IL-10 protein was noticed with increasing 
Etifoxine incubation in both the RAW can C8-B4 treated cells.  However, no statistical 
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significance is seen between any of the treated groups and the untreated control.  Also, 
there was no increase in IL-10 protein observed when different TSPO ligands are used 
(Figure 10).  
 
TSPO Overexpression 
Based on the previous experiments completed in this study we observe that no 
concentration or incubation is appropriate to obtain a significant level of IL-10 mRNA or 
protein production.  This lack of production could be attributed to the lack of activity of 
the Etifoxine molecule or with the mechanism of agonist activation.  Therefore a stable 
cell line was created that overexpresses TSPO compared to cellular endogenous levels.  
The cell line will produce high levels of TSPO and will confirm whether or not IL-10 can 
be augmented through TSPO.   
Previous experiments to create a RAW overexpressing cell line using lipid 
transfection methods proved to be difficult to achieve (data not shown), therefore a stable 
cell line was created through viral infection.  Several viral particle constructs were 
produced by constructing distinctly tagged TSPO gene vectors and packaging them 
within lentivirus.  After two or more rounds of infection RAW cells were given fresh 
culture media and allowed to achieve 95% viability.  RNA was then extracted from the 
various overexpressing cell lines and measured for TSPO and IL-10 mRNA using RT-
PCR as an endpoint.  Normal morphology was observed and no reduction in cell viability 
was noticed with overexpression of TSPO.  Based on gene expression analysis by RT-
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PCR TSPO mRNA is highly expressed in all cell lines created, with the greatest 
expression being found on the GFP construct (Figure 13).  However no increase in IL-10 
is found in any overexpressing cell line (Figure 14).  These results taken together with the 
previous dose response and time course experiments demonstrate that ligand activation or 
overexpression of TSPO does not in itself induce upregulation of IL-10.         
In an attempt to determine the total concentration of TSPO being produced by the 
overexpressing cell line a western blot was performed (Figure 15).  A total of 1ug protein 
following BCA analysis for total protein from either culture media or cell lysate for each 
sample was loaded and gel electrophoresis was performed.  Antibodies were probed 
against TSPO and images were obtained through chemiluminescent substrate addition.  
Data suggests that there is minimal difference between cellular levels of TSPO and 












Translocator protein (TSPO), an 18-kDa mitochondrial membrane protein, has 
been studied for its role in several cellular functions, including steroid biosynthesis and 
transport, regulation of reactive oxygen species and immunomodulation.  Recently, 
several studies have focused on the therapeutic neuroprotective and anti-inflammatory 
effects of TSPO in regards to several debilitating CNS related diseases including 
AlzheimerÓs and Multiple Sclerosis (Karlstetter, 2014, Wei, 2013, Sook, 2014).  One 
specific reason for the increase in interest is due to the fact that normally low levels of 
neuronal TSPO increase dramatically during traumatic brain injuries and neuronal 
inflammation (Choi, 2011, Kugler, 2008, Girard, 2008).  Another well-known compound 
with established neuronal anti-inflammatory properties is the cytokine IL-10.  Although 
both proteins have been studied for their anti-inflammatory properties no mechanistic 
relationship has yet to be established.  In this present study, we investigated the potential 
relationship between the neuroprotective effects of TSPO and the anti-inflammatory 
characteristics of IL-10.  
In order to verify this, several experiments were conducted to determine whether 
continuous activation of TSPO triggers an increase in cellular IL-10 production.  To 
achieve the effective activation of TSPO several highly specific ligands were 
investigated.  The most notable ligand for TSPO is the drug Etifoxine, which is an 
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established therapy used for patients with anxiety related disorders (Rupprecht, 2010, 
Schlichter, 2000).  Recent studies have demonstrated that binding of Etifoxine to TSPO 
induces the biosynthesis and release of several steroids including pregnenolone, 
progesterone, 5-alpha-dihydroprogesterone and allopregnanolone in both plasma and 
brain tissue samples (Maingat, 2012).  These and other data reveal the potent and 
selective binding of Etifoxine to TSPO.   
To begin this study, I first attempted to establish the relationship that activation of 
TSPO, through ligand interaction, induces IL-10 gene regulation.  The use of quantitative 
polymerase chain reaction (qPCR) for the cataloging of inflammatory and anti-
inflammatory mRNA is a well-established technique (Hirayama, 2013).  Furthermore, 
determining levels of RNA transcript produced by the cells will give some indication of 
the amount of IL-10 protein produced in future experiments.  Although qPCR is generally 
considered a highly sensitive technique, assay and primer specific variations could 
interfere with lower limits of detection.  This incentivizes the use of leukocyte type cells 
in immunomodulation studies since these cells contain the proper machinery to produce 
high levels of cytokines when properly stimulated.   
Since IL-10 gene regulation through TSPO activation is unknown, I conducted a 
dose response and time course set of experiments.  The dose response experiments 
utilized a wide range of Etifoxine concentrations in order to determine if any variation in 
gene modulation could be observed.  In several experiments using several concentrations 
of Etifoxine, I observed no significant difference between the treated samples compared 
 31 
to the untreated controls.  This observation also holds true for both the macrophage and 
microglia cell lines used in this study.  We can conclude from these data that various 
doses of Etifoxine do not affect IL-10 levels of immune modulating cells in either a 
neuronal or non-neuronal context.  It is important to point out that we do observe a 
significant difference between the untreated control group and positive control group 
suggesting that both cell lines are capable of expressing significant amounts of IL-10 
when probed with the proper stimuli.    
Following the dose response experiments, a time course of a static 1ug/mL dose 
of Etifoxine was performed on both macrophage and microglia cell lines.  In agreement 
with the previous results no significant upregulation of IL-10 mRNA was observed in 
either cell line.  Taking both the dose response and time course results into consideration, 
I can conclude that TSPO activation through Etifoxine does not induce IL-10 gene 
modulation.      
Since IL-10 mRNA levels did not increase with the introduction of Etifoxine it 
would be very unlikely that levels of protein would increase.  It is possible to suggest that 
a low level of transcript is necessary to produce protein.  However, the amount of protein 
being produced by such low transcript levels would be undetectable by the standard 
ELISA technique.  In this study we utilized a pre-made IL-10 ELISA kit incorporating a 
standard curve with a multi-log dynamic range and a lower limit of detection of 
10pg/mL.  Supporting the gene expression data, we did not observe any increase in IL-10 
protein production from either cell line in both the dose response or time course 
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experiments.  Interestingly, I did observe an increase in the production of IL-10 protein in 
treated cells after 8 hours of incubation.  However, the increase in protein was not 
significant compared to the basal level in the untreated cells.  This demonstrates the well-
known fact that leukocytic cell lines can produce high levels of cytokines when stressed 
through normal in-vitro culture (Krishnamoorthy, 2006, Medzhitov, 2008).  Therefore I 
can conclude that the increases in protein we observed is a normal process and function 
of both the macrophage and microglia cell lines used.  These data demonstrate 
conclusively that TSPO activation through Etifoxine stimulation does not alter IL-10 
genetic or protein levels. 
The previous experiments showed that no alteration of IL-10 was observed 
suggesting that TSPO does not affect IL-10.  This could be due to the mechanism in 
which Etifoxine binds to TSPO.  Factoring that TSPO has several binding sites for ligand 
interaction, specific molecular interaction to TSPO can induce several varying outcomes 
(Scarf, 2011, Fan, 2010).  If different molecular interactions induce specific 
characteristics, then conceivably the interaction of TSPO to Etifoxine may not induce any 
upregulation of the IL-10 cytokine.  Therefore I obtained several other TSPO ligands, all 
of which have distinct binding sites to TSPO which may induce an increase in IL-10.  
Although the administration of the molecules was well tolerated I did not observe any 
indication of IL-10 mRNA upregulation and no evidence of protein production.  Given 
the results of all experiments performed, we can conclude that activation of TSPO 
through drug interaction does not induce IL-10 modulation.       
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Both macrophage and microglia cell lines have abundant TSPO binding sites 
(Karlstetter, 2014).  However, the levels of receptor in both of these lines may be 
inadequate for the upregulation of the IL-10 cytokine.  In order to determine whether or 
not increases in the levels of TSPO would induce an upregulation of IL-10, we created 
several cell lines overexpressing the TSPO protein.  Based on the gene expression levels, 
all the cell lines produced were found to have vast quantities of TSPO transcript available 
for ligand binding interaction, and subsequent IL-10 stimulation.  However, when these 
cells were assayed for levels of IL-10 mRNA no significant increase in transcript was 
observed.  Consequently, I then checked the protein levels for both the cellular lysate and 
cultured media on all the overexpressed cell lines.  We found that although all cell lines 
had large amounts of transcript level this did not necessarily promote the production of 
more protein at the cellular level.  Interestingly, we do observe small increases of TSPO 
protein in the cultured media of the overexpressing cells.  Since TSPO has not been 
shown to be a secreted protein the fact that we observe significant levels could be due to 
membrane saturation and aggregation of the protein.   
 
Study Limitations 
The non-significant results obtained in this study may be due to the limitations of 
the techniques used.  Aside from adjusting assay parameters we must first determine the 
activity of the molecule we are testing.  The normal engagement of TSPO through it 
various ligands increase the level of cholesterol transport and induce the activation of 
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steroidogenesis (Scarf, 2011).  Therefore a way to determine compound activity may be 
to monitor their individual effect on intracellular cholesterol efflux.  Another method 
would be to prompt the activation of TSPO and assay for steroid end products known for 
their anti-inflammatory properties.  Unfortunately, there are few readily available assay 
kits for this purpose and each assay would need alteration and optimization for each of 
the cell lines used in this study.  
Another important factor within this study is the 1ug/mL dose of Etifoxine used in 
many of the gene expression and protein production experiments.  Since no literature 
source has mentioned the use of Etifoxine for the stimulation of IL-10 the selected 
concentration was based on previously determined levels of toxicity in culture (Figure 1).  
Furthermore, a total of one dose was selected for the promotion of IL-10 within the cell.  
Although examination into the experimental methods sections of several recent 
publications did not elucidate the use of multiple doses within a given experiment, it may 
be possible that additional doses of Etifoxine are needed for IL-10 regulation in this 
studies context.  Therefore adjustment of the total amount of Etifoxine within the 
experimental design may be needed to fully determine the effect of Etifoxine on IL-10 
production.  
Alternatively, the use of the RAW264.7 macrophage cell line for IL-10 detection 
may not have been the optimal choice.  The selection of RAW cells for this study was 
based upon their use in multiple publications for the study of cytokine modulation upon 
the stimulation of the inflammatory mediator LPS.  However, it is important to note that 
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the detection of IL-10 after the use of LPS, in this study, was determined to be highly 
variable.  This point is most clearly illustrated when observing the levels of IL-10 
mRNA, in the LPS lane (Figure 1, Lane 2), between several of studies experiments.  If 
the expression of the IL-10 is variable from experiment to experiment when using the 
LPS positive control, then the same amount of variability will most likely be observed for 
any given test article.  Therefore, pinpointing an accurate dose and incubation time for 
the Etifoxine in the RAW264.7 cell line may be difficult to obtain. 
Finally, several cell lines were created that overexpressed the TSPO protein.  This 
was done to determine if high levels of endogenous TSPO are needed for the modulation 
of IL-10.  Although these overexpressed cells were assayed for the production of both IL-
10 mRNA and protein, no attempt was made to induce IL-10 production with the 
administration of Etifoxine.  Consequently, the next reasonable experiment to perform in 
this study would be to determine if the TSPO overexpressed cells are responsive to 
Etifoxine administration.  If we find that no significant change is observed to IL-10 in the 
inflammatory mediator cells overexpressing our target protein of interest, then our 
conclusion of no direct relationship between IL-10 and TSPO would be considered more 
robust.     
 
Future Directions 
Prior to data demonstrating their binding affinity to TSPO, the drugs used in this 
study were first determined to effectively bind to the receptor apf"tgegrvqt"uwdv{rgu"qh"Ȗ-
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aminobutyric acid type (GABA) (Suryanarayanan, 2012).  The GABA receptors main 
function is to modulate neurotransmission through the flow of potassium and chloride 
ions through neuronal cells.  Data has shown that upregulation of IL-10 reduces the flow 
potential of GABA and its subtypes promoting the anti-inflammatory properties of 
several cytokines (Suryanarayanan, 2012).  Furthermore, the proposed mechanism for 
TSPO ligand therapy for CNS related diseases is the upregulation of neurosteroids and 
their potentiation of pre and post synaptic pathways and the reduction of inflammation 
(Table 8, Rupprecht, 2010).  These data sets suggest that a mechanism for modulation of 
IL-10 through TSPO would be observed with an increase in protective neurosteroids and 
the reduction of neuronal GABA function.  Therefore it may be possible to determine IL-
10 upregulation within the introduction of known neurosteroids. 
One other important factor when assessing the up and down regulation of 
signaling factors within the CNS is the neuron-specific microenvironment.  Functionally, 
overexpression of TSPO is considered mainly due to the excessive activation and 
subsequent trafficking of immune modulating cells, such as microglia, to the site of 
inflammation.  This, in turn, results in the production of anti-inflammatory neurosteroids 
and subsequent reduction in activated microglia through the TSPO/ligand binding 
interaction (Table 8, Rupprecht, 2010).  However, it has also been noted that aside from 
the direct mediation of inflammation by microglia, inflamed neurons are also able to 
induce the activation of TSPO as well (Table 9, Rupprecht, 2010).  This is witnessed by 
Girard et al, who found that stimulating PC12 with Etifoxine induced axonal outgrowth 
and increased neuronal proliferation (Girard et al, 2008).  This particular experiment is 
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important since PC12 cells only express TSPO binding sites and do not have functional 
GABA receptors.  Furthermore the affinity for the TSPO antagonist PK11195 was starkly 
different when compared to microglia and Schwann cells (Costa et al, 2005).  This 
suggests that certain factors are required within the neuron-specific microenvironment to 
induce the production of anti-inflammatory actions.  Further study is needed to 
understand whether changes within the microenvironment would cause a modulation of 
IL-10.    
 
Conclusion 
The primary aim of this study was to investigate whether the activation of TSPO 
through stimulation with Etifoxine would promote the production of the anti-
inflammatory cytokine IL-10.  Although I conducted several relevant experiments, we 
did not observe any changes in gene or protein levels.  From the data we can conclude 
that a direct mechanism involving TSPO and IL-10 may not exist.  Even though the data 
in this study does not correlate the reduction in neuronal inflammation to IL-10 the 











Table 1.  IL-10 Signaling Pathway.  IL-10 binds to the IL-10 receptor and activates 
both JAK1 and TYK2 kinases.  Activation of these kinases stimulate the phosphorylation 
of STAT3 the formation of the STAT3 complex and the subsequent translocation to the 




Table 2.  DNA Vector Maps.  TSPO insert was cut using SgfI and MluI enzymes 
(NewEnglandBio) and amplified by PCR.  TSPO was run on agarose gel, clipped and 
purified using Qiaquick gel extraction kit (Qiagen).  Ligase of TSPO into the lentiviral 







Component Volume for One Reaction 
RT-PCR Mix 10 µL 
Gene Expression Assay 1 µL 
RT Enzyme Mix 0.5 µL 
RNA template 10ng/uL 
+ RNase-free Water  
8.5 µL 
Total Volume 20.0 µL 
 
Table 3. RT-PCR Reaction Mixture.  Purified total RNA from treated cells were 
equally diluted to a concentration of 10ng/ul and mixed with either gene expression assay 
kits for IL-10, TSPO or the house keeping control18s.  Samples were placed onto RT-










Stage Step Temp Time 





95°C 10 min 
Cycling 
(40 cycles) 
Denature 95°C 15 sec 
Anneal/Extend 60°C 1 min 
 
Table 4. RT-PCR Cycle Conditions.  Samples being analyzed for mRNA upregulation 
used a one-step RNA to Ct method from Applied Biosystems.  Typical one-step cycle 














 Logic Experiment Controls and Why 
1. 
Dose response experiment with 
TSPO ligand Etifoxine to 
determine optimal concentration 
of TSPO to elicit IL-10 gene 
expression. 
Treat RAW 264.7 cells 
with various 
concentrations of 
Etifoxine for 24 hours. 
Controls include cells that 
are untreated to determine 
baseline expression or 
treated with LPS to 
determine positive IL-10 
expression. 
2. 
Time course experiment with 
Etifoxine to determine optimal 
incubation of the TSPO ligand for 
IL-10 gene expression. 
Treat RAW cells with 
single dose of Etifoxine 
and incubate for various 
time points. 
Controls include cells that 
are untreated to determine 
baseline expression or 
treated with LPS to 
determine positive IL-10 
expression. 
3. 
Protein expression experiment 
with Etifoxine to determine 
whether TSPO ligand treatment 
can induce IL-10 protein 
production. 
Treat RAW cells with 
single dose of Etifoxine 
and incubate for 24 
hours. 
Controls include cells that 
are untreated to determine 
baseline protein 
production or treated with 
LPS to determine positive 
IL-10 protein production. 
4. 
Gene expression experiment with 
the microglia cell line C8-B4 to 
determine if Etifoxine is able to 
induce IL-10 mRNA in a neuronal 
macrophage cell line. 
Treat C8-B4 cells with 
conditions established 
by RAW cell 
experimentation. 
Controls include cells that 
are untreated to determine 
baseline expression or 
treated with LPS to 
determine positive IL-10 
expression. 
5. 
Protein expression experiment 
with the C8-B4 microglia cell line 
to determine if Etifoxine is able to 
promote production of IL-10 
protein in a neuronal macrophage 
cell line. 
Treat C8-B4 cells with 
conditions established 
by RAW cell 
experimentation. 
Controls include cells that 
are untreated to determine 
baseline protein 
production or treated with 
LPS to determine positive 
IL-10 protein production. 
 
Table 5.  Overview of Experimental Approach.  The experiments completed in order 
to determine IL-10 upregulation through TSPO activation. 
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Steps Gene Expression Protocol Protein Production Protocol 
1.) 
Plate cells into a 12 well tissue culture plate 
at 3x10^5 per well in the presence of DMEM 
w/10%FBS - Overnight incubation 
Plate cells into a 12 well tissue culture 
plate at 3x10^5 per well in the presence 
of DMEM w/10%FBS - Overnight 
incubation 
2.) 
Treat cells with either 10ug/mL LPS (+ Ctrl) 
or the TSPO ligand Etifoxine at 10ug/mL - 
Untreated wells (- Ctrl)  
Treat cells with either 10ug/mL LPS (+ 
Ctrl) or the TSPO ligand Etifoxine at 
10ug/mL - Untreated wells (- Ctrl)  
3.) Incubate cells for 2 and 4 hours - wash and prepare cells for RNA extraction 
Incubate cells for 24 and 36 hours - 
take media samples from wells at 
given time points 
4.) 
Follow Qiagen RNAeasy protocol for 
extracting totalRNA from the treated and 
untreated RAW cells 
Samples are run on the R&D systems 
Mouse IL-10 ELISA kit using 
manufacturers protocol 
5.) 
Extracted totalRNA will be analyzed for 
concentration and purity using A260/A280 
spectrophotometer 
Protein levels determined by 
absorbance levels via a 
spectrophotometer  
6.) 
50ng of totalRNA along with qPCR master 
mix and either assay probes for IL-10 or 18s 
will be plated onto a 96-well qPCR reaction 
plate 
Treated and untreated samples 
compared  
7.) qPCR run using manufacturers required instructions   
8.) 
Gene expression signatures from treated and 
wpvtgcvgf"ygnnu"vtcpuncvgf"vq"ǻǻEV"
comparison method  
  
 
Table 6. Experimental Protocols.  Both gene expression and protein production 




Untreated Untreated LPS 1ug/mL LPS 1ug/mL 
Etifoxine 0.1ug/mL Etifoxine 0.1ug/mL Etifoxine 1ug/mL Etifoxine 1ug/mL 
Etifoxine 10ug/mL Etifoxine 10ug/mL Etifoxine 100ug/mL Etifoxine 100ug/mL 
 
Table 7.  Typical Experimental Plate Layout.  This is a typical IL-10 gene expression 










Table 8.  Anti-Inflammatory Mediation of Inflamed Neurons through Etifoxine.  
Inflammation of neurons in the CNS induces the activation and subsequent trafficking of 
microglia cells to the site of injury.  TSPO promotes the release of neurosteroids which 
regulates neurotransmitter GABA and initiates an anti-inflammatory response.  Etifoxine 
is able to act on both GABA and TSPO to reduce neurotransmission and increase 




Neuron Etifoxine bound to 
GABA Receptor 
reduces ion flux 
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Table 9.  Anti-Inflammatory Mediation of Inflamed Neurons through TSPO.  
Inflammation of neurons in the CNS can also lead to release of neurosteroids from 
neuronal expressed TSPO.  The released neurosteroids regulate the neurotransmitter 







GABA function which 
reduces inflammation 
TSPO can release anti-
inflammatory neurosteroids 
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Figure 1. RAW Cell IL-10 Gene Expression Dose Response, 4 Hour.  Raw cells were 
plated and treated with Etifoxine at the concentrations stated in duplicate sample groups.  
Incubation with drug was for a total of for 4 hours after which RNA was extracted and 
assayed for IL-10 gene expression with 18s used as house keeping control.  LPS was 
treated at 1ug/mL and statistical significance (p<0.5) was obtained by comparing the 
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Figure 2. RAW Cell IL-10 Gene Expression Dose Response, 16 Hour.  Raw cells 
were plated and treated with Etifoxine at the concentrations stated in duplicate sample 
groups.  Incubation with drug was for a total of for 16 hours after which RNA was 
extracted and assayed for IL-10 gene expression with 18s used as house keeping control.  
LPS was treated at 1ug/mL and statistical significance (p<0.5) was obtained by 
comparing the relative quantification if the treated groups and the untreated group with a 
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Figure 3. RAW Cell IL-10 Gene Expression Time Course.  Raw cells were plated and 
treated with Etifoxine at a concentration of 1ug/mL.  Incubation with drug was for a total 
of the incubations times stated in duplicate sample groups, after which RNA was 
extracted and assayed for IL-10 gene expression with 18s used as house keeping control.  
LPS was treated at 1ug/mL and statistical significance (p<0.5) was obtained by 
comparing the relative quantification if the treated groups and the untreated group with a 
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Figure 4. RAW Cell IL-10 Gene Expression Dose Response, Various Compounds.  
Raw cells were plated and treated with 4-Chlorodiazepam, PK11195, N,N-Dihexyl-2-(4-
fluorophenyl)indole-3-acetamide and Etifoxine at the concentrations stated in duplicate 
sample groups.  Incubation with drug was for a total of for 4 hours after which RNA was 
extracted and assayed for IL-10 gene expression with 18s used as house keeping control.  
LPS was treated at 1ug/mL and statistical significance (p<0.5) was obtained by 
comparing the relative quantification if the treated groups and the untreated group with a 
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Figure 5. C8-B4 Cells IL-10 Gene Expression Dose Response.  C8-B4 cells were 
plated and treated with Etifoxine at the concentrations stated in duplicate sample groups.  
Incubation with drug was for a total of for 4 hours after which RNA was extracted and 
assayed for IL-10 gene expression with 18s used as house keeping control.  LPS was 
treated at 1ug/mL and statistical significance (p<0.5) was obtained by comparing the 
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Figure 6. C8-B4 Cells IL-10 Gene Expression Time Course.  C8-B4 cells were plated 
and treated with Etifoxine at a concentration of 1ug/mL.  Incubation with drug was for a 
total of the incubations times stated in duplicate sample groups, after which RNA was 
extracted and assayed for IL-10 gene expression with 18s used as house keeping control.  
LPS was treated at 1ug/mL and statistical significance (p<0.5) was obtained by 
comparing the relative quantification if the treated groups and the untreated group with a 
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Figure 7. RAW Cell IL-10 Protein Production Dose Response, 4 Hour.   Raw cells 
were plated and treated with Etifoxine at the concentrations stated in duplicate sample 
groups.  Incubation with drug was for a total of for 4 hours after which cell culture media 
was taken from the cells and assayed for IL-10 protein expression using the Quantikine 
IL-10 ELISA from R&D Systems.  LPS was treated at 1ug/mL and statistical significance 
(p<0.5) was obtained by back-ecnewncvkpi"cnn"rncvg"cduqtdcpegÓu"vq"c"mpqyp"KN-10 control 
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Figure 8. RAW Cell IL-10 Protein Production Dose Response, 16 Hour.  Raw cells 
were plated and treated with Etifoxine at the concentrations stated in duplicate sample 
groups.  Incubation with drug was for a total of for 16 hours after which cell culture 
media was taken from the cells and assayed for IL-10 protein expression using the 
Quantikine IL-10 ELISA from R&D Systems.  LPS was treated at 1ug/mL and statistical 
significance (p<0.5) was obtained by back-ecnewncvkpi"cnn"rncvg"cduqtdcpegÓu"vq"c"mpqyp"
IL-10 control and comparing the treated groups and the untreated groups using a two-
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Figure 9. RAW Cell IL-10 Protein Production Time Course.  Raw cells were plated 
and treated with Etifoxine at a concentration of 1ug/ml.  Incubation with drug was for a 
total of the incubation times stated in duplicate sample groups after which cell culture 
media was taken from the cells and assayed for IL-10 protein expression using the 
Quantikine IL-10 ELISA from R&D Systems.  LPS was treated at 1ug/mL and statistical 
significance (p<0.5) was obtained by back-ecnewncvkpi"cnn"rncvg"cduqtdcpegÓu"vq"c"mpqyp"
IL-10 control and comparing the treated groups and the untreated groups using a two-
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Figure 10. RAW Cell IL-10 Protein Production Dose Response, Various 
Compounds.   Raw cells were plated and treated with 4-Chlorodiazepam, PK11195, 
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide and Etifoxine at the concentrations 
stated in duplicate sample groups.  Incubation with drug was for a total of 4 hours after 
which cell culture media was taken from the cells and assayed for IL-10 protein 
expression using the Quantikine IL-10 ELISA from R&D Systems.  LPS was treated at 
1ug/mL and statistical significance (p<0.5) was obtained by back-calculating all plate 
cduqtdcpegÓu"vq"c"mpqyp"KN-10 control and comparing the treated groups and the 
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Figure 11. C8-B4 Cell IL-10 Protein Production Dose Response.  C8-B4 cells were 
plated and treated with Etifoxine at the concentrations stated in duplicate sample groups.  
Incubation with drug was for a total of 4 hours after which cell culture media was taken 
from the cells and assayed for IL-10 protein expression using the Quantikine IL-10 
ELISA from R&D Systems.  LPS was treated at 1ug/mL and statistical significance 
(p<0.5) was obtained by back-ecnewncvkpi"cnn"rncvg"cduqtdcpegÓu"vq"c"mpqyp"KN-10 control 
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Figure 12. C8-B4 Cells IL-10 Protein Production Time Course.  C8-B4 cells were 
plated and treated with Etifoxine at a concentration of 1ug/ml.  Incubation with drug was 
for a total of the incubation times stated in duplicate sample groups after which cell 
culture media was taken from the cells and assayed for IL-10 protein expression using the 
Quantikine IL-10 ELISA from R&D Systems.  LPS was treated at 1ug/mL and statistical 
significance (p<0.5) was obtained by back-ecnewncvkpi"cnn"rncvg"cduqtdcpegÓu"vq"c"mpqyp"
IL-10 control and comparing the treated groups and the untreated groups using a two-
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Figure 13. RAW Cell Overexpressing TSPO Gene Expression.  RAW cells were 
infected with the various lentivirus constructs listed.  After infection of 2 days cells were 
allowed to incubate for 1 week prior to RNA being extracted and assayed for TSPO 
mRNA levels using 18s as a house keeping control.  Statistical significance (p<0.5) was 
obtained by comparing the relative quantification of the stable cell lines and the 
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Figure 14. RAW TSPO Overexpressing Stable Cell Line IL-10 Gene Expression.   
TSPO overexpressing RNA was assayed for IL-10 mRNA overexpression using 18s as 
the house keeping control.  Statistical significance (p<0.5) was obtained by comparing 
the relative quantification of the stable cell lines and the uninfected cell line with a two-














Figure 15. TSPO Protein Production in Overexpresing Cell Lines.  Cultured media 
and cellular lysate were loaded at 1ug total protein onto a 14% electrophoresis gel.  
Samples were probed with antibodies against TSPO and images were obtained through 
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